NASDAQ:VACC Vaccitech (VACC) Stock Forecast, Price & News $2.46 -0.04 (-1.60%) (As of 10:51 AM ET) Add Compare Share Share Today's Range$2.46▼$2.5050-Day Range$2.19▼$2.5152-Week Range$2.02▼$7.45Volume2,416 shsAverage Volume49,100 shsMarket Capitalization$94.34 millionP/E RatioN/ADividend YieldN/APrice Target$12.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Vaccitech MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside412.8% Upside$12.67 Price TargetShort InterestHealthy0.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.84Based on 2 Articles This WeekInsider TradingAcquiring Shares$36,575 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.39) to ($2.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 starsMedical Sector447th out of 981 stocksPharmaceutical Preparations Industry212th out of 484 stocks 3.5 Analyst's Opinion Consensus RatingVaccitech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.67, Vaccitech has a forecasted upside of 412.8% from its current price of $2.47.Amount of Analyst CoverageVaccitech has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.06% of the float of Vaccitech has been sold short.Short Interest Ratio / Days to CoverVaccitech has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vaccitech has recently increased by 43.66%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVaccitech does not currently pay a dividend.Dividend GrowthVaccitech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VACC. Previous Next 2.1 News and Social Media Coverage News SentimentVaccitech has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Vaccitech this week, compared to 2 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaccitech insiders have bought 0.76% more of their company's stock than they have sold. Specifically, they have bought $36,575.00 in company stock and sold $36,300.00 in company stock.Percentage Held by InsidersOnly 6.00% of the stock of Vaccitech is held by insiders.Percentage Held by InstitutionsOnly 27.07% of the stock of Vaccitech is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vaccitech are expected to decrease in the coming year, from ($2.39) to ($2.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaccitech is -6.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaccitech is -6.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaccitech has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vaccitech (NASDAQ:VACC) StockVaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Read More Receive VACC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter. Email Address VACC Stock News HeadlinesJune 3, 2023 | americanbankingnews.comRobin Wright Buys 13,750 Shares of Vaccitech plc (NASDAQ:VACC) StockMay 19, 2023 | finance.yahoo.comNewsflash: Vaccitech plc (NASDAQ:VACC) Analysts Have Been Trimming Their Revenue ForecastsJune 8, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.May 17, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Arcus Biosciences (RCUS), Vaccitech Plc (VACC)May 16, 2023 | msn.comMorgan Stanley Maintains Vaccitech plc - ADR (VACC) Overweight RecommendationMay 12, 2023 | msn.comVaccitech: Q1 Earnings InsightsMay 12, 2023 | finance.yahoo.comVaccitech Reports First Quarter 2023 Financial Results and Recent Corporate DevelopmentsMay 5, 2023 | finance.yahoo.comRevenues Working Against Vaccitech plc's (NASDAQ:VACC) Share PriceJune 8, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.April 17, 2023 | finance.yahoo.comVaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity ProfileMarch 31, 2023 | americanbankingnews.comInsider Selling: Vaccitech plc (NASDAQ:VACC) CEO Sells 15,000 Shares of StockMarch 31, 2023 | americanbankingnews.comHC Wainwright Equities Analysts Reduce Earnings Estimates for Vaccitech plc (NASDAQ:VACC)March 30, 2023 | marketwatch.comGlobal Influenza Vaccines Market Size 2023 to 2026 Size and Share Survey ReportMarch 30, 2023 | americanbankingnews.comShort Interest in Vaccitech plc (NASDAQ:VACC) Declines By 16.6%March 29, 2023 | markets.businessinsider.comVaccitech Plc (VACC) Gets a Buy from Morgan StanleyMarch 29, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Kodiak Sciences (KOD) and Vaccitech Plc (VACC)March 29, 2023 | americanbankingnews.comVaccitech (NASDAQ:VACC) PT Lowered to $15.00March 28, 2023 | finanznachrichten.deVaccitech plc: Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis BMarch 28, 2023 | finance.yahoo.comVaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis BMarch 28, 2023 | americanbankingnews.comBarclays Trims Vaccitech (NASDAQ:VACC) Target Price to $7.00March 27, 2023 | msn.comVaccitech Earnings Perspective: Return On Capital EmployedMarch 27, 2023 | benzinga.comUK leadership in health, food and sustainability prompts Milltrust to launch follow-on university venture fund.March 27, 2023 | msn.comNew $150m fund set to invest in ‘high-impact’ firms across food and healthcareMarch 25, 2023 | americanbankingnews.comVaccitech plc (NASDAQ:VACC) to Post FY2022 Earnings of $0.26 Per Share, HC Wainwright ForecastsMarch 24, 2023 | finanznachrichten.deVaccitech plc: Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate DevelopmentsMarch 24, 2023 | msn.comBanking Sector Worries Weigh on American Depositary Receipts of European EquitiesMarch 24, 2023 | benzinga.comVaccitech shares are trading higher after the company reported better-than-expected FY22 sales results.See More Headlines VACC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VACC Company Calendar Last Earnings3/24/2023Today6/08/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VACC CUSIPN/A CIK1828185 Webwww.vaccitech.co.uk Phone44-18-6581-8808FaxN/AEmployees33Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.67 High Stock Price Forecast$16.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+412.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$5.34 million Net Margins-51.19% Pretax Margin-65.00% Return on Equity-6.33% Return on Assets-5.65% Debt Debt-to-Equity RatioN/A Current Ratio16.74 Quick Ratio16.74 Sales & Book Value Annual Sales$44.70 million Price / Sales2.12 Cash Flow$0.27 per share Price / Cash Flow9.22 Book Value$6.52 per share Price / Book0.38Miscellaneous Outstanding Shares38,350,000Free Float36,048,000Market Cap$94.72 million OptionableNot Optionable Beta0.16 Key ExecutivesMr. William J. Enright MBA (Age 60)CEO & Director Comp: $916.62kDr. Margaret Marshall M.D. (Age 66)Chief Medical Officer Comp: $662.04kMs. Sarah GilbertCo-FounderMr. Adrian Hill Ph.D.Co-Founder & Scientific AdvisorMs. Gemma Brown (Age 33)CFO & Company Sec. Mr. Chris Ellis (Age 63)Chief Operating Officer Dr. Nadege Pelletier Ph.D. (Age 45)Chief Scientific Officer Mr. Graham Griffiths (Age 44)Chief Bus. Officer Ms. Elizabeth Eagling-Vose M.B.A.Head of Clinical OperationsBernie McDonaldHead of IPMore ExecutivesKey CompetitorsSpero TherapeuticsNASDAQ:SPROGalectin TherapeuticsNASDAQ:GALTSpruce BiosciencesNASDAQ:SPRBBriaCell TherapeuticsNASDAQ:BCTXEton PharmaceuticalsNASDAQ:ETONView All CompetitorsInsiders & InstitutionsRobin WrightBought 13,750 shares on 5/25/2023Total: $36,575.00 ($2.66/share)Liontrust Investment Partners LLPSold 144,152 shares on 5/15/2023Ownership: 1.189%Renaissance Technologies LLCBought 11,400 shares on 5/12/2023Ownership: 0.030%Ipswich Investment Management Co. Inc.Bought 5,700 shares on 4/24/2023Ownership: 0.071%William EnrightSold 15,000 sharesTotal: $36,300.00 ($2.42/share)View All Insider TransactionsView All Institutional Transactions VACC Stock - Frequently Asked Questions Should I buy or sell Vaccitech stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccitech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VACC shares. View VACC analyst ratings or view top-rated stocks. What is Vaccitech's stock price forecast for 2023? 2 brokers have issued 1-year price objectives for Vaccitech's shares. Their VACC share price forecasts range from $7.00 to $16.00. On average, they anticipate the company's share price to reach $12.67 in the next twelve months. This suggests a possible upside of 412.8% from the stock's current price. View analysts price targets for VACC or view top-rated stocks among Wall Street analysts. How have VACC shares performed in 2023? Vaccitech's stock was trading at $2.35 at the beginning of 2023. Since then, VACC stock has increased by 5.1% and is now trading at $2.47. View the best growth stocks for 2023 here. Are investors shorting Vaccitech? Vaccitech saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 20,400 shares, an increase of 43.7% from the April 30th total of 14,200 shares. Based on an average daily trading volume, of 52,800 shares, the short-interest ratio is currently 0.4 days. Currently, 0.1% of the company's stock are short sold. View Vaccitech's Short Interest. When is Vaccitech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our VACC earnings forecast. How were Vaccitech's earnings last quarter? Vaccitech plc (NASDAQ:VACC) posted its quarterly earnings results on Friday, March, 24th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.12. The business had revenue of $6.46 million for the quarter, compared to analysts' expectations of $3.07 million. Vaccitech had a negative trailing twelve-month return on equity of 6.33% and a negative net margin of 51.19%. When did Vaccitech IPO? (VACC) raised $110 million in an IPO on Friday, April 30th 2021. The company issued 6,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. What is Vaccitech's stock symbol? Vaccitech trades on the NASDAQ under the ticker symbol "VACC." Who are Vaccitech's major shareholders? Vaccitech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Liontrust Investment Partners LLP (1.19%), Ipswich Investment Management Co. Inc. (0.07%) and Renaissance Technologies LLC (0.03%). Insiders that own company stock include Christopher Ellis, Graham Griffiths, Joseph Scheeren, Karen A Dawes, M&G Investment Management Ltd, Robin Wright, Sciences Innovation Plc Oxford and William Enright. View institutional ownership trends. How do I buy shares of Vaccitech? Shares of VACC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vaccitech's stock price today? One share of VACC stock can currently be purchased for approximately $2.47. How much money does Vaccitech make? Vaccitech (NASDAQ:VACC) has a market capitalization of $94.72 million and generates $44.70 million in revenue each year. The company earns $5.34 million in net income (profit) each year or ($0.40) on an earnings per share basis. How can I contact Vaccitech? Vaccitech's mailing address is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. The official website for the company is www.vaccitech.co.uk. The company can be reached via phone at 44-18-6581-8808 or via email at ir@vaccitech.co.uk.. This page (NASDAQ:VACC) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.